FWFanfan Wang

Fanfan Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fanfan Wang has a total of 36 co-authors. Here are the top co-authors by number of shared publications:

  • Jian Liu

    Department of Rheumatology and Immunology First Affiliated Hospital of Anhui University of Chinese Medicine Hefei Anhui China

    15 shared publications
  • Mingyu He

    Department of Rheumatism Immunity, The First Affiliated Hospital, Anhui University of Chinese Medicine, Hefei, China

    7 shared publications
  • Jianting Wen

    Department of Rheumatology and Immunology, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, Anhui, 230031, People’s Republic of China

    6 shared publications
  • Qi Han

    The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, 230038, Anhui, China; Anhui Province Key Laboratory of Modern Chinese Medicine Department of Internal Medicine Application Foundation Research and Development, Hefei, 230038, Anhui, China

    6 shared publications
  • Jianting Wen

    Department of Rheumatology and Immunology, First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, China

    5 shared publications
  • Mingyu He

    The First Affiliated Hospital of Anhui University of Chinese Medicine

    4 shared publications

Latest Publications

  • Open Access

    Therapeutic Properties and Underlying Mechanisms of Traditional Chinese Medicine in Managing Rheumatoid Arthritis: An Integrative Review of Clinical and Molecular Findings

    by Jianting Wen, Jian Liu, Lei Wan, Fanfan Wang, Yang Li

    Traditional Chinese medicine (TCM) has a long‐standing history in the treatment of rheumatoid arthritis (RA), known as “Bi Zheng,” and offers a comprehensive therapeutic approach characterized by multi‐target and multi‐pathway mechanisms. Modern pharmacological research has demonstrated that bioactive compounds and herbal formulas derived from TCM (e.g., triptolide [TPL] from Tripterygium wilfordii and the Xinfeng Capsule [XFC]) effectively interfere with the complex pathogenesis of RA. These interventions modulate diverse pathological processes, including the suppression of pro‐inflammatory cytokines (e.g., TNF‐α, IL‐6, and IL‐1β), induction of apoptosis in hyperplastic synovial cells, and regulation of novel cell death pathways (such as ferroptosis and pyroptosis). Furthermore, TCM components exhibit potent antioxidant properties, inhibit pathological angiogenesis, ameliorate hypercoagulable states, and restore gut microbiota dysbiosis, which is increasingly recognized as a key environmental factor in RA development. Notably, emerging evidence highlights the critical role of non‐coding RNAs (ncRNAs) as mediators of these therapeutic effects. Concurrently, a growing body of clinical evidence from randomized controlled trials (RCTs), cohort studies, and real‐world data mining consistently confirms the significant efficacy and safety of TCM interventions in relieving RA symptoms, improving joint function, and reducing disease activity. By integrating preclinical and clinical findings, a robust evidence chain emerges, validating traditional TCM concepts through modern scientific rigor. Therefore, TCM represents a valuable resource for RA drug discovery and integrative treatment strategies. Further in‐depth investigation is needed into its specific molecular targets, optimal formulations, and long‐term clinical outcomes to facilitate its global translation and application.

  • Open Access

    SIRT1 as a Key Regulator in Rheumatic Diseases: Integrating Molecular Insights with Traditional Chinese Medicine Approaches

    by Jianting Wen, Jian Liu, Lei Wan, Fanfan Wang, Yang Li

    Rheumatic diseases are characterized by chronic inflammation and immune dysregulation that profoundly impair patients’ quality of life, yet their underlying pathogenic mechanisms remain incompletely elucidated. Sirtuin 1 (SIRT1), an NAD⁺-dependent deacetylase, has emerged as a pivotal regulatory hub that integrates inflammatory signaling, cellular stress responses, metabolic reprogramming, and epigenetic control. Through key pathways (e.g. NF-κB and AMPK), SIRT1 modulates immune activation, synovial pathology, cartilage degeneration, and systemic inflammatory phenotypes across a spectrum of major rheumatic diseases, including rheumatoid arthritis (RA), osteoarthritis (OA), systemic lupus erythematosus (SLE), and gout. To summarize the current body of evidence, we conducted a targeted literature search across major databases (e.g. PubMed and Web of Science) for publications published up to 2025. We included peer-reviewed original studies and reviews that investigated (a) SIRT1 expression/activity and its downstream mechanisms in rheumatic diseases, or (b) traditional Chinese medicine (TCM) compounds or formulations with experimental or clinical evidence of SIRT1 modulation. We synthesized mechanistic insights spanning immunometabolism, inflammasome regulation, autophagy/ferroptosis, and non-coding (nc)RNA-mediated epigenetic networks. Additionally, we critically discussed context-dependent—and at times conflicting—observations across experimental models and human studies. Furthermore, we evaluated the current landscape of TCM-based SIRT1 modulation and found that most evidence remains preclinical; translational efforts are constrained by bioavailability, standardization, dosing, and reproducibility. Taken together, this integrative review highlights SIRT1 as a biologically important but context-dependent regulatory node in rheumatic diseases. It also emphasizes that SIRT1-targeted interventions (including TCM-derived modulators) require biomarker-guided stratification, pharmacological validation, and rigorously designed clinical studies before they can be translated into clinical practice.

  • Open Access

    Exploring the ubiquitination regulatory network: opening new perspectives for rheumatoid arthritis therapy

    by Fanfan Wang, Jian Liu, Jianting Wen, Yue Sun, Mingyu He

    Rheumatoid arthritis (RA) is a complex autoimmune disorder characterized by chronic systemic inflammation, primarily affecting the joints and synovium, but also involving multiple extra-articular tissues. This persistent inflammation contributes to progressive joint damage and the development of various systemic comorbidities. Despite significant advances in RA research, the underlying pathogenic mechanisms remain incompletely elucidated. Ubiquitination, a critical post-translational modification, regulates protein stability, localization, and function, and is essential in numerous biological processes, including cell signaling, immune regulation, and inflammatory responses. Emerging evidence highlights the pivotal role of ubiquitination in the pathogenesis of RA. This review provides a comprehensive overview of recent advances in the study of ubiquitination in RA, delineates its mechanistic contributions to disease development, and evaluates the therapeutic potential of targeting ubiquitination pathways. By offering new insights into RA pathophysiology, this review lays a theoretical and experimental foundation for the development of more effective, targeted therapeutic strategies, potentially opening new avenues for RA treatment.


  • Open Access

    Association between Xin An Jian Pitongbi Fang and self-perception of patient with osteoarthritis: A case-control study

    by Mingyu He, Jian Liu, Guizhen Wang, Yanyan Fang, Yanqiu Sun, Fanfan Wang

    This study aims to explore the risk and protective factors of Self-perception of patient (SPP) changes in osteoarthritis (OA) patients, and evaluate the improvement effect of Xin An Jian Pitongbi Fang (XAJPF) on SPP. A case-control study design was adopted to recruit OA patients admitted to the Rheumatology Department of the First Affiliated Hospital of Anhui University of Chinese Medicine from February 2024 to December 2024. The binary logistics regression model tested by Hosmer Lemeshow was used to evaluate the risk and protective factors of SPP changes in OA patients. We used self comparison before and after and association rule analysis to investigate the impact of XAJPF on SPP in OA patients. Bootstrap test was used to explore the mediating factors of XAJPF on SPP in OA patients. Finally, the impact of different exposure levels of XAJPF on SPP in OA patients was observed through subgroup analysis. A total of 270 OA patients were included in the study, all of whom had symptoms of varying degrees of joint pain and worsening of SPP. The logistics regression analysis results showed that lifestyle habits (smoking/drinking), advanced age, gender (female), weight, elevated inflammation levels (hypersensitive C-reactive protein and interleukin-6), and coagulation and lipid metabolism disorders were risk factors for SPP deterioration, while the use of XAJPF was a protective factor for SPP. After further analysis, it was found that XAJPF treatment can significantly improve the SPP score of OA patients, and there is a strong correlation with the improvement of SPP scores. The mediation analysis results indicate that restoring lipid metabolism and coagulation function are key links for XAJPF to improve SPP. Subgroup analysis results show that the improvement of laboratory indicators in the high exposed group patients treated with XAJPF combined with XAJPF is significantly different from that in the non exposed group and low exposed group ( P <.05). The above evidence suggests that persistent joint pain severely affects SPP in OA patients, and XAJPF may help improve SPP in OA patients, which can be considered for inclusion in the clinical treatment plan for OA patients.


  • Open Access

    The neutrophil-to-lymphocyte ratio in rheumatoid arthritis: The dual perspectives from literature and clinic

    by Yang Li, Jian Liu, Yuedi Hu, Chengzhi Cong, Yiming Chen, Yanyan Fang

    The aim of this study was to elucidate the research direction and application value of neutrophil-to-lymphocyte ratio (NLR) as an emerging inflammatory marker in rheumatoid arthritis (RA) from both literature and clinical perspectives. Firstly, we made an extensive analysis in terms of the number of publications, highly cited literature, co-cited references, and keywords. Subsequently, a retrospective exploration of clinical data of 1490 patients with rheumatic diseases admitted to the First Affiliated Hospital of Anhui University of Chinese Medicine was conducted. Logistic regression models were used to explore the independent predictive role of NLR in different scenarios. Nomogram was developed and the model was clinically evaluated by recipient operating characteristic (ROC) curves, calibration plots and decision curve analysis. In addition, association rule analysis and Mantel test were used to determine associations between NLR and clinical characteristics and self-perception of patients. A total of 544 articles were retrieved, focusing on the pathophysiology and clinical studies of RA-NLR, such as “disease activity,” “inflammation” and “classification.” Retrospective analysis demonstrated that NLR, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels were significantly higher in RA patients than in non-RA patients. Logistic regression models identified gender, age, NLR, ESR and CRP as independent predictors of RA. The ROC curve determined a cutoff value of 2.258 for NLR and a maximum area under the curve of 0.736. Both association rule analysis and Mantel test showed that NLR was highly correlated with inflammatory markers such as ESR, CRP, and self-perception scale scores before and after treatment. NLR > 2.258 was a meaningful risk factor for moderate-to-severe pain and higher disease activity, which predictive reliability was further confirmed in subgroup stratification analyses. NLR, as a novel inflammatory marker, correlates with clinical characteristics and self-perception of RA patients, acting as an independent predictor of RA diagnosis and activity assessment.


  • Open Access

    Synovial Organoids and Cell Culture Models: An Ideal Platform for Exploring Traditional Chinese Medicine in Rheumatoid Arthritis

    by Fanfan Wang, Jian Liu, Jianting Wen, Yue Sun, Mingyu He

    Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by synovial hyperplasia, inflammation, and pannus formation. Although conventional therapies are effective, they are often associated with significant side effects. Traditional Chinese medicine (TCM), known for its high safety profile and multitarget therapeutic effects, has shown unique potential in the treatment of RA. In vitro models, including synovial organoids and cell culture systems, serve as crucial platforms for replicating the structure and function of human synovial tissue. Synovial organoids closely mimic the pathological microenvironment of RA, providing an ideal tool for drug screening and efficacy evaluation. In contrast, cell culture models, which offer greater experimental flexibility, allow precise control of conditions to facilitate an in-depth investigation of the roles and mechanisms of individual or interacting cell types in RA pathogenesis. This review first covers the fundamental structure and pathophysiology of the synovium, followed by a detailed discussion of the development and construction techniques of synovial organoids. Building on this foundation, it explores the therapeutic potential of TCM using synovial organoids and cell culture models, highlighting how TCM exerts therapeutic effects by inhibiting synovial hyperplasia and modulating immune responses through its multitarget and multipathway mechanisms. Finally, the review envisions the broad application prospects of integrating synovial organoids and cell culture models with TCM in RA treatment, underscoring the importance of interdisciplinary collaboration and innovation. This study aims to provide a novel perspective on the integration of TCM with modern biotechnological approaches and promote innovative advances in RA therapy.


  • Crosstalk between N6-methyladenosine modification and ncRNAs in rheumatic diseases: therapeutic and diagnostic implications

    by Jianting Wen, Jian Liu, Lei Wan, Yue Sun, Fanfan Wang

    Background In eukaryotic cells, N6-methyladenosine (m6A) is the most prevalent RNA methylation modification and plays a fundamental role in regulating diverse biological processes through the modulation of non-coding RNA (ncRNA) expression and activity. The role of m6A modification in developing rheumatic diseases is crucial but remains inadequately studied. Methods Characterized by pain and inflammation, rheumatic diseases like rheumatoid arthritis (RA), osteoarthritis (OA), ankylosing spondylitis (AS), and systemic lupus erythematosus (SLE) are autoimmune disorders. Recent findings emphasize the importance of m6A modifications and non-coding RNAs in the biological processes underlying rheumatic diseases. Results This review elucidates the fundamental concept of m6A modification and the associated research methodologies. Subsequently, it systematically consolidates modern knowledge on the influence of m6A regulators and m6A modification-related ncRNAs on rheumatic diseases, incorporating perspectives on traditional Chinese medicine interventions. Conclusions Offering a comprehensive overview of m6A-related ncRNAs in the context of rheumatic diseases, this review proposes new therapeutic avenues by targeting m6A modification pathways.


  • Open Access

    Comprehensive review of patients with hypercoagulable state in rheumatoid arthritis and strategies to reduce readmission rates: A retrospective cohort study based on protective exploration of traditional Chinese medicine

    by Yang Mm Li, Jian Liu, Yuedi Hu, Chengzhi Mm Cong, Yiming Mm Chen, Fanfan Wang

    This study aimed to investigate the effect of traditional Chinese medicine (TCM) intervention on the risk of readmission and laboratory indicators in patients with rheumatoid arthritis hypercoagulable state. In the retrospective cohort design, patients with RA hospitalized between June 2013 and June 2021 at the First Affiliated Hospital of Anhui University of Chinese Medicine were followed up by telephone. Propensity score matching (PSM) was used to balance deviations in baseline information between patients in the hypercoagulable (HC) and non-hypercoagulable (Non-HC) groups, with exposure defined as receiving TCM treatment for ≥ 1 month. Cox proportional hazards model and Kaplan–Meier survival curves were employed to determine the factors influencing the readmission of RA-HC patients. Mantel test and association rule analysis was used to explore the relationship between the included factors and laboratory indicators. A total of 1169 cases were successfully followed up, including 831 RA-HC patients. 1:2 PSM yielded 311 patients in the non-HC group versus 535 patients in the HC group. We observed that the incidence of readmission and surgical treatment was significantly higher in the HC group than in the non-HC group, while the incidence of readmission, surgical treatment, and all-cause mortality was much lower in the exposed group than in the non-exposed group (all P < .05). Based on the Cox proportional risk model, we identified age above 60 years, Sjogren’s syndrome, neutrophil count, and neutrophil-lymphocyte ratio (NLR) as risk factors for readmission, with TCM playing a protective role. The Kaplan–Meier survival curves further showed that the risk of readmission in the high-exposure subgroup was markedly lower than that of the low-exposure subgroup. Furthermore, the Mantel test highlights an intrinsic correlation between coagulation markers and other markers such as erythrocyte sedimentation rate (ESR) and hypersensitive c-reactive protein (hs-CRP), which are dramatically influenced by gender, age, etc. In addition, association rule analysis revealed a strong correlation between TCM and non-readmission, as well as improvement in rheumatoid factor, hs-CRP, ESR, platelet count, and NLR in RA-HC patients. As a promising therapeutic strategy, TCM with sufficient intensity and duration interventions can effectively reduce the risk of readmission and relieve laboratory indicators in RA-HC patients.


  • Xinfeng capsule inhibits lncRNA NONHSAT227927.1/TRAF2 to alleviate NF-κB-p65-induced immuno-inflammation in ankylosing spondylitis

    by Yanyan Fang, Jian Liu, Ling Xin, Hui Jiang, Jianting Wen, Xu Li, Fanfan Wang, Mingyu He, Qi Han


  • Open Access

    Hypercoagulability in Rheumatoid Arthritis: A Bibliometric Analysis and Retrospective Data Mining Study

    by Fanfan Wang, Jian Liu, Yanyan Fang, Jianting Wen, Mingyu He, Qi Han, Xu Li

    Background: Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic systemic inflammation, leading to joint deformities and functional loss. RA progression is accompanied by abnormalities in the coagulation-fibrinolysis system, clinically manifested as a hypercoagulable state. However, there are currently no bibliometrics or visualization analysis in this field. Objective: The present study aims to reveal the knowledge structure, research status, and research trends related to hypercoagulability in RA through bibliometric analysis and to evaluate the utility of inflammatory and coagulation markers in RA disease activity through retrospective data mining. Methods: English articles and reviews on RA hypercoagulability published from 2010 to 2023 were extracted from the Web of Science Core Collection (WoSCC) database on March 1, 2023. VOSviewer and CiteSpace software were used for knowledge mapping analysis of the included papers in terms of countries/regions, institutions, journals, authors, keywords, research hotspots, and frontiers. A retrospective analysis was conducted on the general information on RA patients. The demographic and clinical indicators of all participants were collected to determine the correlation of inflammatory and coagulation markers with the Chinese patient-reported activity index for rheumatoid arthritis (CPRI-RA). Results: A total of 957 papers were retrieved. The United States was the most productive country in this field and had the highest h-index, and the most prolific institution was the Karolinska Institute. The Annals of the Rheumatic Diseases was the journal with the most publications, and KLARESKOG L. was the most productive author. From keyword analysis, it could be seen that "inflammation", "activation", "disease-activity", and "risk" had long been the focuses of RA hypercoagulability research. "Criteria", "validation", "coagulation", "target", and "anemia" were the latest popular keywords in the past 5 years. Retrospective data mining revealed that the levels of inflammation (RF, ESR, and CRP) and coagulation (PLT and DD) were significantly increased in RA patients. FBG, CRP, and ESR were significantly correlated with CPRI-RA. Additionally, ESR, CRP, and FBG were identified as independent risk factors for CPRI-RA. Conclusion: The mechanism and application of hypercoagulability in RA have been research hotspots in recent years. Inflammation and coagulation markers are independent risk factors for CPRI-RA.